Central AsianResearch Index

Giant Cell Tumor of Bone in the Era of Denosumab: Indications, Outcomes and Controversies

Giant cell tumor of bone is a locally aggressive neoplasm characterized by RANKL-driven osteoclast activation. Denosumab has significantly changed its management. The objective of the review was to analyze the results and controversies of the use of denosumab in giant cell tumor of bone, clinical outcomes and unresolved controversies to make clinical decisions and identify priority areas for future research. Methods. A narrative review was performed using PubMed, EMBASE, and Cochrane databases (2010–2025). Studies were selected based on relevance, study design, and clinical impact, including randomized trials, prospective studies, and large retrospective series. The collected data were reviewed and synthesized with particular focus on tumor biology, indications for denosumab therapy, treatment outcomes, recurrence patterns, adverse effects, resistance mechanisms, and current controversies related to the management of giant cell tumor bone. Results. Denosumab demonstrates high response rates and reduces surgical morbidity for giant cell tumor bone. However, concerns remain regarding recurrence, treatment duration, and long-term safety. Conclusion. Denosumab is an effective treatment option in selected patients, but careful patient selection and long-term monitoring are essential.

Сведения

Опубликовано
2026 · С. jto056
Язык
Английский
ISSN
2789-9632 · 2789-9640
Издатель
National Scientific Center of Traumatology and Orthopaedics named after Academician N.D. Batpenov